Results 61 to 70 of about 4,927 (252)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review

Journal of Ophthalmology, 2021
Corticosteroids are used in a variety of ophthalmological diseases. One challenge faced by ophthalmologists is to deliver corticosteroids to the posterior segment of the eye with efficacy and safety.
Flávio Ribeiro, Manuel S. Falcão
doaj   +1 more source

Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management [PDF]

, 2016
INTRODUCTION: With the increasing use of intravitreal administration of corticosteroids in macular edema, steroid-induced intraocular pressure (IOP) rise is becoming an emergent issue.
Denis, P, Diestelhorst, M, Figueiredo, AR, Garway-Heath, DF, Goñi, FJ, Nordmann, J-P, Stalmans, I, Taylor, S   +7 more
core  

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations [PDF]

, 2020
Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting ...
Abraldes, M., Adán, A., Armadá, F., Ascaso, F.J., Cabrera, F., Cervera, E., Figueroa, M.S., Pazos, M., Pessoa, B., Reyes, M.Á., Udaondo, P.   +10 more
core   +3 more sources

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, Gerhard Garhöfer, Martina Cartwright, Markus Müller, Iris Kopeloff, Luigi Moro, Nicholas Squittieri, Alessandro Mazzetti   +8 more
wiley   +1 more source

Fluocinolone Acetonide Ophthalmic ??? Bausch & Lomb

Drugs in R & D, 2005
Bausch & Lomb and Control Delivery Systems have developed an intravitreal implant that can deliver the corticosteroid fluocinolone acetonide [fluocinolone acetonide implant, Retisert] to posterior eye tissue for up to 3 years. The implant uses Bausch & Lomb's Envision TD technology.
openaire   +2 more sources

The determination of fluocinolone acetonide in formulated products

Journal of Pharmacy and Pharmacology, 1966
Abstract A chromatographic procedure for the determination of fluocinolone acetonide is described. The method employs a hexane: dioxan: water partition system supported on Celite. The progress of the chromatogram is followed by measurement of the ultraviolet absorption of eluate fractions at 238 mμ.
A. Holbrook, F. Bailey, R. J. Miller
openaire   +2 more sources

Efficacy of Botulinum Toxin A for the Management of Melasma: A Split‐Face, Randomized Control Study

Journal of Cosmetic Dermatology, Volume 24, Issue 8, August 2025.
ABSTRACT Background Melasma management remains challenging due to its multifactorial nature pathogenesis and recurrent nature. Previous studies showed positive effects of botulinum toxin A (BoNT‐A) for treating and preventing ultraviolet‐induced hyperpigmentation.
Sasipim Chaijaras, Suphagan Boonpethkaew, Sonphet Chirasuthat, Nawara Sakpuwadol, Tanat Yongpisarn, Pimsiri Anansiripun, Vasanop Vachiramon   +6 more
wiley   +1 more source

Pathogenesis of Melasma Explained

International Journal of Dermatology, Volume 64, Issue 7, Page 1201-1212, July 2025.
Pathophysiology of melasma. ABSTRACT This review provides an in‐depth analysis of the pathophysiology of melasma and highlights recent studies that elucidate its underlying mechanisms. Given the prevalence of melasma, a thorough understanding of its pathogenesis is critical for the development of effective treatment strategies.
Lara Ali, Firas Al Niaimi
wiley   +1 more source

Predictors of Long-Term Visual Outcome in Intermediate Uveitis [PDF]

, 2017
PURPOSE: To describe factors that predict visual loss and complications in intermediate uveitis. DESIGN: Cross-sectional study. PARTICIPANTS: Subjects with intermediate uveitis were identified from a database of 1254 uveitis patients seen ...
Bar, A, Lightman, SL, Niederer, RL, Sharief, L, Tomkins-Netzer, O   +4 more
core   +1 more source